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In this mini review, we aim to evaluate the structure and function of Human Endogenous Retroviruses 
(HERVs) with respect to the benefit they may have for humans or the damage they may cause. 
Emphasis is laid on their putative roles, if any, in pregnancy, in gene regulation and in cancer. As a 
basis for this discussion it will first be necessary to briefly describe the structure and function of 
retroelements, including HERVs, before addressing their positive or negative effects at the cellular and 




The recent sequencing of the entire human genome revealed that almost half consists of transposable 
elements (TEs), namely DNA transposons (2.8%; 0.3 x 106 copies) and the more abundant 
retroelements (42.2%; 2.7 x 106 copies).1,2,3 DNA transposons amplify without RNA intermediates, 
whereas retroelements (as the name implies) require a reverse transcriptase to retrotranscribe RNA 
into DNA copies that will subsequently integrate into chromosomal DNA. TEs have often been 
regarded as ‘‘selfish DNA’’ or ‘‘junk DNA,’’ but it remains unclear whether they are really all ‘‘junk,’’ 
because upon becoming part of our genome, like all genes they are subject to natural selection and 
can be co-opted for the benefit of the host. Indeed, it may well turn out that TEs, in addition to other 
already measurable positive effects (some of which are described below), may play a major role in 
shaping our genome by increasing its plasticity and in the evolution of mammalian gene regulation 
networks.4–7  
 
HERVs belong to the retroelements, which can be subdivided into those with regulatory long terminal 
repeats (LTRs, 8.3% of our DNA; 0.3 x 106 copies) and retroelements without LTRs (33.9%; 2.4 x 106 
copies) (Fig. 1). Among the non- LTR members, short and long interspersed elements (SINEs and 
LINEs, respectively) are present in very high copy numbers. SINEs cannot code for proteins whereas 
LINEs encode a reverse transcriptase (RT) that can be utilized by both SINEs and LINEs for 
retrotranspositions or for the formation of pseudogenes. It is unknown whether the LINE RT can also 
be used by additional retroelements like HERVs for retrotransposition. The LTR containing 
retroelements can be grouped into 6 superfamilies.8 Class I–III HERVs possess limited nucleotide 
sequence homologies to C-, B- or spumaretroviruses, respectively. The other superfamilies MER4, 
MST and MLT represent ancient retrotransposons not known to be still functional in humans today. 
 
 
Basic Genomic Organization and Replication of HERVs 
 
To discuss the functions of HERVs that make up 8% of the human genome, one needs to look at their 
genetic organization. 1,9 All exogenous and preserved endogenous retrovirus strains have the basic 
genetic order 50-gag-pro-pol-env-30. Gag codes for matrix and capsid proteins, pro for protease, pol 
for reverse transcriptase, RNase H and integrase and env for envelope, as illustrated in Figure 2 for 
the youngest and most active human endogenous retrovirus family HERV-K. In particular, exogenous 
viruses, notably HIV, possess additional non-structural accessory genes that facilitate their replication 
or impair host defenses (reviewed in Ref. 10). These accessory genes are rare in endogenous virus 
strains, with the exception of HERV-K (see below).  
 
Retroviruses are characterized by the outstanding and unique features of their replication that have 
consequences for their hosts. Virus particles contain 2 copies of RNA of ~8 to 10 kb in length. Reverse 
  
transcription from fragile single-strand viral particle RNA into relatively stable doublestrand DNA 
reverts the usual flow of genetic information and leads to constitutive integration of the DNA provirus 
into host chromosomes. Most retroviruses prefer active genes or transcription start sites for 
integration.11,12 Proviruses in gene-rich regions of the chromosomes tend to become inactivated or 
excised, resulting over time in a disproportionate 
accumulation of proviral sequences in gene-sparse regions, consistent with an integration effect on 
gene expression that typically reduces fitness. There is no other virus family that constitutively requires 
chromosomal integration for their replication. Only retroviruses exist in exogenous plus endogenous 
form, the latter in all cells of (usually) all members of a given host species as a result of germ-line 
infection of ancestors millions of years ago.4,13,14 
 
 
Mechanisms of Retroviral Malignant Cell Transformation 
 
Although most retroviruses tend to integrate in gene-rich regions, insertional mutagenesis has 
nevertheless been more often demonstrated for LINEs than for HERVs in humans and other animals 
(see below). Newly integrated proviral DNA possesses identical long terminal repeats at the 30- and 
50-ends with primer binding sites and promoter and enhancer domains.  
 
Downstream promotion or expression enhancement of cellular genes can be a consequence of 
proviral chromosomal integration.15–17 Furthermore, retroviruses, like other viruses such as 
herpesviruses, are capable of incorporating cellular genes, albeit at the expense of their structural 
genes. When retroviruses transduce cellular proto-oncogenes during reverse transcription due to 
template-switching of the RT 
they become dependent on co-infecting wild-type viruses to provide structural proteins. Historically, 
much of our knowledge of oncology has been gained by the investigation of acutely transforming 
retroviruses carrying oncogenes (reviewed in Ref. 18–20). 
 
A few replication-competent retroviruses encode their own oncogenic protein, notably Rous sarcoma 
viruses of chickens with their src-oncogene, the tax gene of the exogenous human T-cell lymphoma 
virus (HTLV) or the env gene of the Jagsiekte sheep retrovirus (reviewed in Ref. 21). Oncogenic 
retroviral proteins stimulate cell proliferation, often by influencing signaling pathways or levels of 
cytokine production that leads to growth stimulation and/or immune suppression. When searching for 
novel human retroviruses or investigating the role of HERVs in human cancer one has to take into 
account the different strategies developed by retroviruses to induce cellular proliferation and cancer 
and be aware that novel strains may use strategies as yet unknown.22 
 
 
Germ-Line Infections of Humans 
 
The discovery of replication-competent exogenous retroviruses that can be oncogenic in natural hosts 
such as mice, sheep or cats (Fig. 3) and at the same time exist in endogenous form stimulated the 
search for corresponding viruses in humans, i.e., the HERVs. In the pre-PCR era, several approaches 
were used for their discovery. 
 
Low stringency hybridization of human genomic libraries using probes derived from conserved pol-
regions of animal retroviruses led, for example, to the detection of retroviral sequences now known to 
belong to the youngest HERV-K family.23 In another experimental approach, highly conserved animal 
retrovirus proteins such as Gag were used in immunological 
assays to screen for cross-reacting antibodies in healthy human blood donors and in patients.24,25 
The detection of such antibodies in patients suffering from germ cell tumors led to attempts to grow 
these tumor cells in vitro and this resulted in the discovery of ‘‘Human Teratocarcinoma-Derived 
Retroviruses’’ (HTDV) in the late 1970s,26 which subsequently were shown to belong to the HERV-K 
family.27  
 
Members of the HERV-K family of human ERVs possess a number of distinguishing features that 
make them attractive for intensive research. Ono et al. sequenced the first HERVK10 genome23,28 
and found it to be surprisingly well conserved. The presence of only a few nonsense mutations 
suggested either recent infection or an ongoing process of purifying selection. HERV-K first integrated 
into the germ-line of Old World primate ancestors some 35 million years ago. Since then, and in 
contrast to other HERV members, repeated proliferation bursts have resulted in more than 60 
  
proviral copies and over 2,500 solitary LTRs.4,29 Re-infection of the germ-line (rather than 
retrotransposition) by replication- competent HERV-K was predominantly responsible for this 
amplification. Indeed, since the divergence of the human and chimpanzee lineages some 6 million 
years ago, the insertional rate of new integrations has remained constant, amounting by now to over 
70 human-specific viral insertions of which 15–20 are highly preserved full-length proviruses. 
30,31 A replication-competent infectious virus clone has not yet been rescued from the human 
genome but single cycle infectivity has recently been demonstrated by consensus sequence clones of 
human-specific HERV-K(HML-2), the youngest known active group of HERV-K elements.32,33  
 
About 10% of the human-specific HML-2 loci are polymorphic, i.e., are present only in a minority of 
human alleles as provirus, single LTRs or as result of an other recombination event.34 These most 
recently integrated elements have not (yet) penetrated the entire human population. Their timepoint of 
germ-line infection can be estimated by the degree of homology between their LTR sequences at the 
50- 
and 30-ends as these LTRs are identical at the time of integration and about 300,000 years are 
needed for each mismatch. In particular, HERV-K113, which is located on chromosome 19 in about 
30% of African and 10% of Caucasian populations, appears to be one of the youngest additions to 
the HERV family with age estimates for the initial germ-line infection of human ancestors ranging from 
200,000 years35 to 2 million years (own observations) ago. HERV-K, including HERV-K113 on 
chromosome 19, is the only human ERV with proviral elements retaining open reading frames for all 
viral genes.36  
 
A comparison of amino acid changes between various human-specific HERV-K(HML-2) loci has 
enabled us to define the original sequence at the time of initial integration. A correspondingly modified 
and cloned ancestral HERVK113 sequence then allowed a functional analysis of viral 
RNAs and proteins.32 Although viral RNAs, proteins and viral particles (Fig. 4A) could be detected in 
transfected cells, productive replication has not yet been observed—due to viral processing defects or 
inhibition by host cellular factors.  
 
Over the last 10 years, a variety of laboratories have added evidence that the various loci of HERV-K 
elements can code for all structural, regulatory and enzymatic viral proteins (reviewed in Ref. 4, 22, 
37) and it was stated that ‘‘HERV-K 113 is an excellent candidate for an endogenous retrovirus that is 
capable of reinfecting humans today’’ (from Ref. 36). 




Beneficial Functions of HERVs 
 
To explain their evolutionary conservation, it is necessary to consider the potential beneficial functions 
that HERVs provide for their hosts. In particular, we need to explain why animal and human ERVs 
have, over millions of years, retained open reading frames and all necessary functional domains in 
some of their proviral chromosomal loci. What functions do the corresponding viral RNAs and proteins 
have?  
 
A more broadened view of transposable elements (TEs), including HERVs, demonstrates that it is the 
autonomous LINE 1 family that accounts for a large part of the human genome (500,000 copies) and 
that by self-mobilization and trans-mobilization of nonautonomous Alu (1.1 million copies) TEs and 
processed pseudogenes (11,000 copies) drive the shaping of the human genome by providing reverse 
transcriptase and promoter function. The vast majority of retrotransposition events are either neutral or 
deleterious to the genome and the latter will be eliminated by negative selection. 39,40 In addition, L1-
L1 recombination contributes to sequence deletions, a process that generates genomic variation. 39 
The complexity and redundancy of human gene regulation networks and the long evolutionary time-
scale required to recognize marginally improved phenotypes makes it difficult to decipher the possible 
benefit afforded by such a generation of variation by deletion.  
 
Fortunately, there are recognizable beneficial innovations resulting from the action of TEs, including 
HERVs.41–43 For example, at least 50% of the human-specific (i.e., young on an evolutionary time-
scale) HERV-K(HML-2) LTRs act in vivo as active promoters for host non-repetitive DNA transcription, 
44 demonstrably contributing to the expression of nearby genes (reviewed in Ref. 8, 16). 
Retrotransposon-mediated sequence transduction and gene duplication lead to the creation of novel 
genes41,45 and fosters the diversity of multigene families such as MHC- or T-cell receptor 
  
genes.46,47 TEcoded RT was also shown to repair chromosomal breaks.48 It has also been 
suggested that the telomerase required to replicate 
and stabilize the ends of chromosomes is derived from TE RT.49 HERV LTRs often contain binding 
sites for the p53 regulator.7 In fact, HERV LTRs account for over 30% of all p53 binding sites genome-
wide and may have been co-opted as regulatory sequences to expand the p53 transcriptional 
network.7 Thus, these HERV LTRs may contribute to the anti-oncogenic function of the stress-
responsive p53 pleiotropic regulator.  
 
Furthermore, HERV-W envelope glycoproteins can confer cellular resistance to superinfection by 
exogenous retroviruses as shown in vitro.50 Interference inhibition of infection by exogenous, 
potentially oncogenic or immunosuppressive retrovirus strains is a general feature in animal 
retrovirology.  
 
A clinically impressive example of cancer immunotherapy has very recently been described.51 HERV-
E, which is apparently activated in a proportion of renal cancer cells, was shown to provide target 
antigens recognizable by cytotoxic T-cells from donors after allogeneic hematopoetic stem cell 
transplantation. This therapeutic approach led to complete (10%) or partial (30%) tumor regression in 
patients and underlines that the natural host is apparently not immunologically tolerant to HERV.  
 
Of even greater significance is the fact that the placentas of primates, including humans,52 produce 
retrovirus particles. 53–55 Originally observed by electron microscopy and later supported by the 
demonstration that the trophoblast specific human growth factor pleiotrophin (PTN) is under the control 
of a HERV LTR,56 these results prompted studies of HERV expression in placentas. In 
syncytiotrophoblasts, but not in cytotrophoblasts, high levels of HERV-W and HERV-FRD envelope 
proteins are demonstrable, named syncytin- 1 and syncytin-2, respectively,57–59 and additional 
HERV env proteins were subsequently detected in syncytiotrophoblasts. 58,60 Retrovirus envelope 
proteins are anchored in the lipid bilayer membrane of both viral particles and cell surface membranes 
and initiate the fusion of viral and cellular membranes during the infection process. In cases where the 
cell surface viral envelope protein can interact with its receptor on adjacent cells, they have also been 
shown to cause fusion of infected and uninfected cells. Thus, the cell–cell fusogenic activity mediated 
by HERV Env proteins probably contributes to the physiological placenta morphogenesis by mediating 
fusion of cytotrophoblasts to 
syncytiotrophoblasts.61  
 
Placentas are, from the viewpoint of the mother, allogeneic organs and the reasons for maternal 
tolerance are still only poorly understood. The fetal multinucleated villous syncytiotrophoblast layer 
acts as the fetal-maternal interface and is responsible, among other functions, for trophic and 
hormonal exchange. At this boundary, immunological tolerance has to be effective to prevent 
allogeneic rejection of the fetus. It is therefore not at all surprising that the already known 
immunosuppressive property of retroviral Env proteins could also be demonstrated for syncytin-2 and 
other HERV Env proteins, although not for syncytin-1.61 HERVs may therefore be instrumental in 
safe-guarding placenta morphogenesis, physiology and fetal–maternal tolerance. Downregulation and 
abnormal intracellular localization of placental syncytin expression may contribute to the etiology of 
pre-eclampsia.62 Similar fusogenic and immunosuppressive endogenous retrovirus proteins were 
recently detected in all rodents tested63 as well as in sheep,64 which suggests positive selection over 
millions of years. 
 
 
Detrimental Effects of HERVs 
 
HERVs have not, of course, evolved primarily for the benefit of the host and are therefore likely to also 
have detrimental effects (Table 1). These can best be understood by first considering the disease-
inducing properties of exogenous human retroviruses.  
 
It is sufficient to summarize that there are 4 well-characterized exogenous retroviruses, namely human 
T-lymphotropic virus Type 1 (HTLV-1) and HTLV-2 and the notorious human immunodeficiency 
viruses HIV-1 and HIV-2. The only unequivocal human tumor retrovirus is HTLV-1, causing 
monoclonal adult T-cell leukemia in a minority (1– 2%) of the infected people, often after latency 
periods of up to 50 years. It is the Tax protein of HTLV-1 that promotes cellular proliferation by 




HTLV-2 was isolated from a patient with hairy cell leukemia but probably does not possess significant, 
if any, oncogenic potential. HTLV-2 may also cause neurological myelopathy or paraparesis.66  
 
HIV-1 and HIV-2 are obviously the cause of AIDS, the greatest medical catastrophe of modern times. 
It is amazing that these 4 virus strains were all isolated within a very brief time period between 1980 
(HTLV-1) and 1986 (HIV-2), during an intense period of scientific activity (described, for example, by 
Anders Vahlne67). It is perhaps surprising that opportunistic tumors in AIDS are not directly caused by 
HIV-1 or HIV-2, given that billions of virus particles are produced by billions of HIV-infected cells in 
millions of HIVpositive people every day. There should be ample opportunity for insertional 
mutagenesis of tumor suppressor genes or downstream promotion or incorporation of cellular 
protooncogenes. For reasons not readily understood, these events appear to be thankfully very rare in 
HIV infection and may in fact be due to the very short life of most productively infected cells.68 
Opportunistic tumors defining AIDS are instead the consequence of immune dysfunction, a fact that 
underlines the significance of an effective immune system in tumor surveillance.  
 
A recently discovered presumably exogenous retrovirus may now have to be added to this list: XMRV 
(Fig. 4B), a virus related to a xenotropic murine leukemia virus (over 95% sequence homology), has 
been isolated from stromal cells surrounding human prostate cancer tissues and from the 
hematopoetic cells of these patients.69,70 Positive specimens were, for the most part, obtained from 
patients with a polymorphism in the RNaseL gene that results in an impaired innate immune system 
because of a reduced interferonresponse to infections.70 PCR amplification of viral sequences from 
different patients revealed >98% nucleotide sequence homology and the sequence can easily be 
distinguished from murine retrovirus genomes because of a characteristic deletion upstream of the 
gag-gene and unique point mutations. XMRV integration sites have been mapped from tumor 
tissues69 and after in vitro infection of the human prostate cancer cell line DU14571 and have been 
shown to locate preferably in GC-islands, DNase hypersensitive sites and gene-dense regions close to 
transcription start sites. However, a common integration site near cellular proto-oncogenes or tumor 
suppressor genes was not found. High-titer XMRV production by a prostate carcinoma cell line has 
also been very recently reported.72  
 
These results still need to be confirmed by other laboratories and an etiological role in prostate cancer 
has yet to be demonstrated. As XMRV is detected in only about 1% of prostatic stromal tissue and in 
hematopoetic but not carcinoma 
cells,70,71 an indirect paracrine mechanism for viral oncogenicity has been suggested.73 A 
preference for XMRV integration in the regulatory region of transcriptionally active genes could alter 
gene expression, resulting in a stromal microenvironment favorable for tumor initiation and/or 
progression and escape from immune surveillance.73,74  
 
We have recently screened more than 600 clinical tumor samples, including prostate cancer biopsies, 
for XMRV infection, without a single positive result. About 13% of the patients were homozygous and 
35% were heterozygous for the functionally impaired RNaseL allel R462Q previously described to be 
present in the vast majority of XMRV-positive prostate cancer patients. The reason for this 
discrepancy is not yet clear. It is possible that geography might play a role, as we studied patients 
from Germany whereas the Silverman laboratory69 had a cohort of patients from the United States. As 
the mode of transmission of XMRV is entirely unclear and its prevalence is unknown, additional 
studies of prostate cancer patients from other areas, including the US, are urgently needed. In 
addition, the mechanism of tumorigenesis needs to be clarified, as does the origin of XMRV, which 
may be an example of zoonotic transmission from mice to humans. Indeed, it is possible that XMRV is 
associated with other human diseases, even with other human tumors. 
 
 
Human Endogenous Retroviruses and Cancer 
 
HERVs have been associated for decades with 2 types of chronic human diseases: autoimmunity and 
cancer. The scientific literature has been littered with premature claims associating known or novel 
retroviruses or their footprints (viral DNA- or RNA-sequences, reverse transcriptase activity, proteins, 
etc.) with human disease. Little has withstood subsequent scientific scrutiny and in the times of 
advanced PCRand genome-wide chip technologies we will focus on those situations in which the 




The possible role of HERVs in autoimmune disease would also be beyond the scope of this mini 
review and the topic has anyway been addressed in a detailed, comprehensive and elegant review.19 
The take-home message of the authors is that ‘‘the notion that the cause of any of these complex 
diseases is due to a single infectious etiological agent is most likely naive’’ (from Ref. 22).  
 
As mentioned earlier, oncogenic animal retroviruses can transform normal cells by 3 main 
mechanisms: (i) capture of cellular oncogenes resulting in acutely transforming, replication 
incompetent virus strains requiring co-infection with wild-type helper viruses for replication, (ii) 
insertional mutagenesis destroying tumor suppressor genes, or, in a related mechanism (iii) 
downstream promotion of adjacent growthpromoting cellular genes. Only animal endogenous 
retroviruses that concomitantly exist also in an exogenous, horizontally transmissible form can use all 
3 mechanisms. Notable examples include mouse leukemia and mouse mammary tumor viruses (MLV, 
MMTV), feline leukemia viruses (FeLV), porcine endogenous retroviruses (PERV) and koala 
retroviruses (KoRV).75,76 The exogenous strains only induce tumors rarely in outbred animal 
populations and usually replicate without causing severe symptoms. Unambiguous evidence for a 
causal oncogenic role of endogenous virus strains has only 
been found in somewhat artificial models, namely in mice bred for rapid tumor development caused, 
for example, by MLV or MMTV or the mouse melanoma-associated MelARV virus strain, a 
recombinant between different endogenous MLVs.  
 
In this regard, it is interesting that very high titers of pelletable HERV-K RNA and reverse transcriptase 
activity can be found in plasma of patients with certain lymphomas and breast cancers77 and these 
titers drop dramatically after cancer treatment. A causal relationship between HERV-K expression and 
tumor development has not (yet) been established and these observation urgently need confirmation 
by other laboratories.  
 
As mentioned earlier, there is no evidence that an infectious, horizontally transmissible HERV actually 
exists, although this cannot be categorically excluded as such a strain would probably not be very 
prevalent in the human population because of strong negative selection. Cellular proteins such as the 
APOBEC (apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like) cytidine deaminases 
enzyme family and the tripartite motif (TRIM) 5-alpha protein can inhibit retrovirus replication in human 
cells, including 
HERVs33,78 and attempts to isolate replication-competent HERVs by co-cultivating putatively infected 
cells with other human indicator cells may therefore be doomed to failure.  
 
As replication-competent HERVs have not yet been unambiguously detected, HERV sequences are 
assumed to be able to play a causative role in cancer development after retrotransposition to novel 
chromosomal loci a subsequent enhancement of growth-promoting cellular genes or inhibition of tumor 
suppressor genes. Furthermore, recombination between the thousands of HERV loci may lead to gain-
offunction sequences. Among all known HERV families, HERV-K(HML-2) is the youngest and 
probably still most 
active provirus. As mentioned before, HERV-K 113 on chromosome 19 has all reading frames open 
and possesses all the regulatory domains required for an infectious retrovirus. Furthermore, the 
HERV-K(HML-2) family possesses 2 accessory viral proteins not found in the other HERVs, namely 
Rec and Np9 (reviewed in Ref. 38). Rec, initially named cORF,79 is a protein functionally related to 
HTLV Rex and HIV Rev, responsible for the nuclear export of unspliced or singlespliced viral mRNA 
into the cytoplasm. Rat-1 cells transfected with rec grew into tumors in nude mice,80 whereas 
these cells transfected with gag or env remained non-tumorigenic. In a related approach, Galli et al.81 
could demonstrate that rec expressed facultatively in transgenic mice may directly contribute to germ 
cell tumor formation as such animals experienced dysfunctions in germ cell development and 
developed carcinoma in situ in a manner reminiscent of precursor lesions of human germ cell tumors. 
It was subsequently shown, again by the laboratory of Mueller- Lantzsch80,82 that both Rec and Np9 
could bind to the promyelocytic leukemia zinc finger protein (PLZF) which is known to be both a tumor 
suppressor and a transcriptional suppressor of the c-myc proto-oncogene. Interestingly, PLZF may 
also be positively involved in regulating spermatogonial stem cell homeostasis in mice.83  
 
Co-expression of both Rec and Np9 proteins abrogated transcriptional repression of the c-myc gene 
by PLZF resulting in increased synthesis of c-Myc protein and of proteins regulated downstream of c-
Myc such as p53. Likewise, cells stably transfected with PLZF and rec exhibited increased cell 
proliferation and reduced apoptosis.  
 
  
Np9-, but not rec- or gag-transcripts were found exclusively in about 50% of a variety of cell lines 
derived from germ cell tumors, breast cancer and leukemias, but not in normal cells or cell lines.84 
This exclusive restriction to tumor cell lines is both astounding and unusual and definitely calls for an 
intensified study of additional tumor lines and biopsies as well as a modern transcriptome analysis.37 
Taken together, Rec and Np9 may even act in concert as oncoproteins in 
GCT via inhibition of PLZF and possibly through interference of Np9 with the Numb/Notch pathway 
essential for proliferative Ras signaling.85 Inhibition of rec- and np9-RNAs by siRNA may revert the 
transformed phenotype of CGT cell lines back to normal.  
 
Only HERV-K has been shown to be able to produce retrovirus particles.9,38 On the basis of the ratio 
of nonsynonomous to synonomous nucleotide changes (>1) that implies purifying selection during 
replication and because of the allelic polymorphism (refer previous section) it has been suggested that 
HERV-K can still replicate via re-infection.30,31 However, a comparison of HERV-K113 and HERV-
K115 frequencies in breast cancer and seminoma patients and in unmatched controls showed no 
differences in their sites of chromosomal integration as would be expected if new horizontal infections 
were occurring. A search for functional HERVs should therefore concentrate on those tumors in which 
virus proteins and particle production has been observed, e.g., ingerm cell tumors and in melanomas.  
 
HERV-K-like particles in human melanomas were first described some time ago86 and, more recently, 
HERVK( HML-2) mRNA and proteins were detected in primary melanomas, in their metastases and in 
melanoma cell lines.87 
Indeed, antibodies and cytotoxic T-lymphocytes specific for HERV-K antigens could be detected in 
melanoma patients.88–90 Attempts to isolate infectious HERV-K particles from melanoma cells were 
not successful but this should now be attempted again by focusing on the HERV-K 113 locus in 
chromosome 19 and the other most recently acquired elements.  
 
HERV may also indirectly facilitate tumor development by the immunosuppressive function of its Env 
proteins. As much as this immunosuppression may be advantageous in syncytiotrophoblasts at the 
fetal–maternal interface as mentioned earlier, it may be detrimental to the immune surveillance of 
tumors. This has recently been shown in elegant experiments using chemically induced allogeneic 
mouse tumors that were rejected after injection into immunocompetent mice. These tumors 
transfected with HERV-K env or with env from Moloney MLV or Mason-Pfizer Monkey Virus (MPMV) 
suppressed tumor rejection and grew in the recipient mice.91,92 The immunosuppressive domain is 
localized in the transmembrane (TM) portion of retroviral Envs93 and the immunosuppressive effects 
of endogenous retroviral envelope proteins have also been demonstrated in mouse melanoma and 
neuroblastoma models (reviewed in Ref. 38). 
 
 
Conclusions and Outlook 
 
We have come a long way since Barbara McClintock’s epochal discovery of transposable elements in 
maize in the 1950s.94 Considering the rapidly increasing knowledge of transposable elements in the 
creation, modulation, regulation and inactivation of eukaryotic genes, we should stop describing them 
as ‘‘junk’’ DNA. Transposable elements are not necessarily useless. They can shape the structure, 
function and networking of the human genome with their promoters, enhancers, polyadenylation 
signals and polymerases.1,5,7,54  
 
ERVs are also TE but do not transpose as easily or as often as LINE or SINE elements. ERVs in 
animal models are involved in tumorigenesis at various levels ranging from infectious, oncogenic 
ERVs to retrotransposition of ERV sequences leading to insertional mutagenesis and downstream 
promotion of genes that themselves promote cell growth. ERV Env proteins are fusogenic and 
immunosuppressive, facilitating tumor escape from immunological surveillance.  
 
In the absence of an infectious HERV, future experimental studies must focus on the indirect 
mechanisms of malignant cell transformation. Because of the high background of thousands of 
mutated HERV sequences, retrotransposition events will be very difficult to detect directly, except 
when they lead to an unusual cellular phenotype by inhibiting or activating cellular gene networks in a 
measurable way. HERVs may act as (initial) co-factors in the complex multi-step development 
of tumors and further analyses should include, for example, inhibition of HERV-K RNA in normal and 
malignant cell lines by siRNA and—in a more general approach—genomewide expression screening 
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Figures and Tables 
 
Figure 1. Classification of the major retroelements, their share of the human genome (in percent) and 







Figure 2. Genomic structure of the HERV-K provirus. The accessory protein Rec is functionally related 
to the HIV protein Rev and the HTLV protein Rex. It shuttles RNA transcripts out of the nucleus. Refer 








Figure 3. Retrovirus strains existing in both endogenous and exogenous replicating forms. With the 















Figure 4. Thin section electron microscopy of retroviral particles. (a) Reconstituted ancestral HERV-
K113 particles. Mature virions with condensed cores are shown in the left hand panel, whereas an 
immature virion and a budding particle are shown in the right hand panel. (b) Image of a mature XMRV 












1Copy number of solo LTRs is given in parentheses. 2For additional details and examples see Ref. 1. 
  
